June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Mesenchymal stem cell based ex vivo gene therapy provides enhanced neuroprotection in X-linked retinoschisis mouse model
Author Affiliations & Notes
  • AMA Bashar
    Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, BC, Canada
  • Andrew Metcalfe
    Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, BC, Canada
  • Ishaq Ahmed viringipurampeer
    Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, BC, Canada
  • Cheryl Gregory-Evans
    Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, BC, Canada
  • Orson Moritz
    Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, BC, Canada
  • Kevin Gregory-Evans
    Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, BC, Canada
  • Footnotes
    Commercial Relationships AMA Bashar, None; Andrew Metcalfe, None; Ishaq Ahmed viringipurampeer, None; Cheryl Gregory-Evans, None; Orson Moritz, None; Kevin Gregory-Evans, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      AMA Bashar, Andrew Metcalfe, Ishaq Ahmed viringipurampeer, Cheryl Gregory-Evans, Orson Moritz, Kevin Gregory-Evans; Mesenchymal stem cell based ex vivo gene therapy provides enhanced neuroprotection in X-linked retinoschisis mouse model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1408.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: X-linked retinoschisis (XLRS) is a juvenile-onset macular degeneration caused by haplo-insufficiency of a cell adhesion protein retinoschisin (RS1), secreted by photoreceptors and bipolar cells. RS1 mutations can lead to secretion of non-functional proteins, thus, as loss-of-function mutations are more amenable to gene therapy, XLRS is an excellent candidate for ex vivo gene therapy. Here, we report the structural and functional benefits observed after intravitreous delivery of MSCs genetically modified to secrete retinoschisin in the retina of our XLRS mouse model.

Methods: MSCs were harvested from syngeneic RS1KO mouse adipose tissue and transfected via electroporation with a plasmid containing human RS1 cDNA under a CMV promoter. Transfected cells were selected using geneticin for two weeks and then assayed by ELISA for retinoschisin synthesis. 200,000 genetically modified MSCs, secreting 8 ng/million cells/day, were injected into the vitreous cavity of the RS1KO mice at the age of post natal day 21. The control groups received either unmodified MSCs or sham injection. Electroretinogram (ERG), optokinetic tracking response (OKT) and histology data were recorded for all cohorts at 2, 4 and 8 weeks post injection time points.

Results: Enhanced neuroprotection and inner nuclear layer tissue integrity were observed in retinas which received modified MSCs injection compare to the sham injection at all three time points. Lower a/b wave ratio in dark-adapted maximal ERG response and increased spatial frequency thresholds in OKT highlighted improvement in preserving vision in this group compared to others. These functional benefits were correlated with increased structural preservation of the inner nuclear layer.

Conclusions: Intravitreal delivery of genetically modified MSCs secreting retinoschisin showed promising results in our XLRS mouse model. Our previously reported magnetic targeting of systemically delivered cells would reduce the collateral damage caused by the intraocular injection of these cells, making this ex vivo approach safer, less-invasive, and repeatable; future investigation will focus on this delivery approach.

Keywords: 696 retinal degenerations: hereditary • 538 gene transfer/gene therapy • 615 neuroprotection  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×